Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function
主要な著者: | Hardman, C, Chen, W, Luo, J, Batty, P, Chen, Y, Nahler, J, Wu, Y, Pavord, I, Erpenbeck, V, Sandham, D, Xue, L, Ogg, G |
---|---|
フォーマット: | Journal article |
出版事項: |
Elsevier
2019
|
類似資料
-
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
著者:: Chen, W, 等
出版事項: (2018) -
Fevipiprant, a selective prostaglandin D-2 receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by group 2 innate lymphoid cells
著者:: Xue, L, 等
出版事項: (2018) -
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
著者:: Sandham, D, 等
出版事項: (2019) -
Fevipiprant, a selective prostaglandin D(2)receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by Tc2 cells (type-2 CD8(+)lymphocytes)
著者:: Xue, L, 等
出版事項: (2019) -
Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells
著者:: Luo, J, 等
出版事項: (2019)